

## Syngene's biologics facility in the U.S.

### MARYLAND

BAYVIEW



**4 Production suites**  
16,000 L SUB capacity  
in the U.S.



**50 L → 4,000 L SUBs**  
Flexible and scalable  
at speed



**50,000 L SUBs**  
Global capacity  
across the U.S. and India

For more information, contact [bdc@syngeneintl.com](mailto:bdc@syngeneintl.com)  
[www.syngeneintl.com](http://www.syngeneintl.com)



Scan the QR code  
to learn more

## Bayview campus overview

Our expanded biologics manufacturing facility in Bayview, Maryland marks a strategic step forward in meeting the growing needs of our global customers.

The addition of this facility increases Syngene's total single-use bioreactor capacity to 50,000 liters, featuring 2,000 and 4,000 liters bioreactors designed to deliver economies of scale.

Furthermore, it ensures continuity of supply for Syngene's customers through its four development and manufacturing facilities located in the U.S. and India, offering services that span cell line development, process optimization, and both clinical and commercial supply.



## Facility highlights

- **Strategic location:** State-of-the-art scalable infrastructure within a major biotech hub.
- **Production capacity:** The facility offers an added 16,000 liters in production bioreactor capacity, featuring 2,000 and 4,000 liters bioreactors to deliver economies of scale.
- **Separate suites:** Three segregated value streams provide flexibility for additional capacity as needed.
- **Unit operations:** Each value stream is equipped with traditional mAb processing equipment, including seed labs, reactor scale-up, filter/centrifuge harvest, multiple chromatography steps, final filtration, buffer and media preparation, and glass washers/autoclaves.
- **Process flexibility:** The use of single-use equipment enables quick and cost-effective updates and additions to unit operations, accommodating any biologics process requirements.
- **Industry-leading equipment:** Equipment from renowned biotech manufacturers (ABEC, Cytiva, Sartorius) ensures reliable performance and a secure supply of components.
- **Pilot area:** A dedicated pilot area supports small-scale development and facilitates seamless transfer to commercial scale operations.



## Operational readiness

- **Commercialization:** The site is Phase 3 ready and equipped to support a Biologics License Application (BLA).
- **Laboratories:** Fully capable laboratories can test materials and products, including specialized microlabs and stability testing capabilities.
- **Cold storage:** Freezer capacity offers over 1,500 square feet, providing -20°C to -80°C storage to support cold chain operations.
- **Utilities:** On-site generation of water for injection (WFI), a process gas tank farm, and back-up generator capabilities ensure reliable and uninterrupted utility supply.
- **Warehouse storage:** The facility is equipped with a warehouse offering 320 pallet positions for raw materials storage.

## How this helps our customers



Greater proximity to the U.S. clients



Total 50,000 L SUB capacity across the U.S. and India



2,000 L and 4,000 L single use bioreactors



Clinical through commercial production



Dedicated mammalian cell culture



Full QC suite in the U.S. with viral clearance testing in India

For more information, contact [bdc@syngeneintl.com](mailto:bdc@syngeneintl.com)  
[www.syngeneintl.com](http://www.syngeneintl.com)



Scan the QR code to learn more



**5901 E Lombard St, Baltimore, MD 21224, United States**

**Syngene**  
Putting Science to Work

#### About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's 6000+ scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb, as well as 2.2 million sq. ft. of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.

For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com) or write to us at [bdc@syngeneintl.com](mailto:bdc@syngeneintl.com)

© 2026 Syngene International Limited, All Rights Reserved.

Stay Connected

